An experimental drug, VX-548, developed by Vertex Pharmaceuticals, could potentially provide effective pain relief without the risk of addiction, according to the company. Unlike opioids that can act on the brain’s perception of pain and are highly addictive, VX-548 works by interrupting pain signals at their source.
In Phase 3 trials involving 3,000 surgery patients, VX-548 demonstrated its efficacy in easing acute pain, comparable to acetaminophen, a common component in medications like Paracetamols and Vicodin. Independent experts have lauded the drug as a potential “blockbuster” that could contribute to combating the opioid crisis. Dr. Stephen Waxman, a neurologist at Yale, expressed optimism, stating, “This has the potential to be a blockbuster. I like to think it’s the beginning of non-addictive medicines for pain.”
Continue reading… “Promising Experimental Drug VX-548 Offers Pain Relief Without Addiction Risk”